Urokinase-Type Plasminogen Activator Protein /Plasminogen Activator Inhibitor Type-1 Protein Selected Reaction Monitoring Assay
Specific peptides are provided that are derived from subsequences of the urokinase-type plasminogen activator protein and the plasminogen activator inhibitor type-1 protein along with assays that can measure those peptides directly in complex protein lysate samples, including protein lysates prepared from histologicaly-processed formalin fixed tissue. The presence and amount of those peptides in samples from a subject can be associated with disease, including cancer, in a subject and provide information about the diagnostic stage/grade/status of the disease/cancer.
1 . A method for measuring levels of the uPA and PAI-1 proteins in a biological sample, comprising detecting at least one fragment peptide from uPA and at least one fragment peptide from PAI-1 in a protein digest prepared from said biological sample using mass spectrometry; and calculating the levels of the uPA and PAI-1 proteins in said sample, wherein said measured levels of the uPA and PAI-1 proteins are independently selected from a relative level or an absolute quantitative level.
2 . The method of claim 1 , further comprising the step of fractionating said protein digest prior to detecting said peptides.
3 - 4 . (canceled)
5 . The method of claim 1 , wherein said protein digest comprises a protease digest.
6 - 9 . (canceled)
10 . The method of claim 1 , wherein the uPA fragment peptide comprises an amino acid sequence as shown in Table 1, and set forth as SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO:8.
11 . (canceled)
12 . The method of claim 1 , wherein the PAI-1 fragment peptide, or peptides, comprises an amino acid sequence as shown in Table 2, and set forth as SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, and SEQ ID NO:18.
13 . The method of claim 12 , wherein uPA peptide identification and characteristics are defined as shown in Table 2 by its specified monoisotopic mass, specified precursor charge state, specified precursor mass over charge ratio (m/z), specified product transition ions (m/z), and specified ion type.
14 . The method of claim 1 , wherein the biological sample comprises blood, urine, serum, ascites, saliva, cells, or tissue.
15 . The method of claim 14 , wherein the tissue is formalin fixed tissue.
16 . (canceled)
17 . The method of claim 14 , wherein the tissue is obtained from a tumor.
18 .- 19 . (canceled)
20 . The method of claim 1 , further comprising quantifying the uPA fragment peptide, or peptides.
21 - 22 . (canceled)
23 . The method of claim 1 , further comprising quantifying the PAI-1 fragment peptide, or peptides.
24 - 27 . (canceled)
28 . The method of claim 1 , further comprising obtaining the biological sample from a subject, wherein detecting the uPA and PAI-1 fragment peptides in the protein digest indicates the presence of uPA and PAI-1 and an association with cancer in the subject.
29 . The method of claim 28 , further comprising correlating detected and quantitated amounts of the uPA and PAI-1 fragment peptides to the diagnostic stage/grade/status of the cancer.
30 . (canceled)
31 . The method of any one of claim 20 or 23 , further comprising selecting a therapeutic treatment for the subject based on the presence, absence, or quantified levels of the uPA and PAI-1 fragment peptides in the protein digest.
32 . The method of any one of claim 20 or 23 , further comprising administering a therapeutically effective amount of a therapeutic agent targeted specifically to the uPA and/or PAI-1 proteins or the level of uPA and/or PAI-1 proteins, wherein the treatment decision about which agent or agents, or the amount of said agent, or agents, used for treatment is based upon specific levels of the uPA and/or PAI-1 fragment peptides in the biological sample.
33 . The method of claim 32 , wherein therapeutic agents include those that specifically bind to uPA and/or PAI-1 proteins and inhibit the biological activity of either uPA or PAI-1.
34 - 36 . (canceled)